Post-transplant diabetes mellitus (PTDM): Managing PTDM involves the early initiation of insulin therapy [120], standard diabetes treatments such as GLP-1 agonists and SGLT2 inhibitors, and optimizing immunosuppressive regimens. The gene discussed is SLC5A2; the disease is diabetes mellitus.